Randomized Trial: Treatments for Pancreatic Cancer Compared

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine – 2 Minute Medicine (free) AND Pancreatic Cancer: mFOLFIRINOX After Surgery Improves Survival – MedicalResearch.com (free)

Related Visual Abstract on Twitter

New #VisualAbstract: FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer https://t.co/PTCVF4PBVe pic.twitter.com/tpornS1b5A

— NEJM (@NEJM) December 20, 2018